-
Recombinant HIV-2 gp36 (390-702)
Recombinant HIV-2 gp36 (390-702)
- 中文名称：
- Recombinant HIV-2 gp36 (390-702)
- 英文名称：
- Recombinant HIV-2 gp36 (390-702)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA38339
- 规格：
- 0.1 mg|0.5 mg|1 mg|2x1 mg|3x1 mg
- 保存建议：
- Stable at 4 degree C for 1 week, should be stored below -18 degree C. Please prevent freeze thaw cycles.
- 货期：
- 6-8周
- 纯度：
- Greater than 95.0% as determined by HPLC analysis and SDS-PAGE.
- 产品形式：
- (1mg/1ml) 0.01M Na2CO3, 0.01M Na3EDTA, 0.014 M?-mercaptoethanol, 0.02% Sarcosyl.
Sterile filtered colorless clear solution.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Description: HIV-2 gp36 34 kDa recombinant has 397 amino acids and contains the sequence of HIV-2 envelope immunodominant regions gp36. The protein is fused to beta-galactosidase (114 kDa) at N-terminus.
Introduction: HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids. Immunodeficiency develops more slowly with HIV-2.HIV-2 is less infectious in the early stages of the virus than with HIV-1.The infectiousness of HIV-2 increases as the virus progresses.Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion. HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25 degree C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition.
